RCT · 2026
Can people tell which drug they got? Blinding tested in a psilocybin and MDMA trial
- Original title
- Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers.
- Authors
- Belinger L, Rieser NM, Engeli EJE, et al.
- Journal
- European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2026
- Molecules
- Psilocybin, MDMA, Other
- Conditions
- Healthy volunteers
- Participants
- 120
- Evidence grade
- Moderate
- Source
- Read the original paper
The question
In psychedelic trials, can participants work out whether they received the real drug or the comparison pill? This study measured how well the blinding held up.
What they did
120 healthy volunteers took part in a double-blind, randomized controlled trial. Each person received psilocybin, MDMA, or methylphenidate, a stimulant used here as an “active placebo” (a comparison drug that produces noticeable effects so it is harder to tell apart from the study drug). Afterwards, participants were asked to guess which substance they had been given, how certain they were, what led them to that conclusion, and what effects they felt.
What they found
Blinding was described as insufficient overall. People who received psilocybin were the most likely to correctly identify what they had taken, MDMA participants fell in the middle, and those given methylphenidate were least likely to guess correctly. Methylphenidate worked better as a stand-in for MDMA than for psilocybin. When the researchers also accounted for how confident people were in their guesses, the picture looked less extreme, with lower rates of correct identification. Participants’ reasons for guessing matched the subjective effects they reported, and previous experience with these substances did not change guessing accuracy.
The fine print
The study involved healthy volunteers, not patients being treated for a condition, so it does not tell us how blinding behaves in clinical populations. The abstract reports patterns rather than specific percentages or statistical results, so the size of the differences cannot be judged. Guesses and certainty ratings are self-reported. This summary is based on the abstract alone.
What it means
In this trial, many participants could tell which substance they had received, especially with psilocybin. That matters because broken blinding can inflate apparent benefits in psychedelic trials, and it supports routinely measuring and reporting blinding rather than assuming it worked.
Evidence grade: Moderate. A randomized, double-blind trial in 120 healthy volunteers, but it measures guessing accuracy rather than a clinical outcome, and the report gives few specific numbers.
This summary is based on the study’s published abstract.